[go: up one dir, main page]

WO2005065604A1 - Pansement - Google Patents

Pansement Download PDF

Info

Publication number
WO2005065604A1
WO2005065604A1 PCT/KR2004/003201 KR2004003201W WO2005065604A1 WO 2005065604 A1 WO2005065604 A1 WO 2005065604A1 KR 2004003201 W KR2004003201 W KR 2004003201W WO 2005065604 A1 WO2005065604 A1 WO 2005065604A1
Authority
WO
WIPO (PCT)
Prior art keywords
layer
wound
dressing
wounds
set forth
Prior art date
Application number
PCT/KR2004/003201
Other languages
English (en)
Inventor
Myung-Hwan Park
Chul-Ho Eo
Pil-Eun Lee
Hyun-Jung Kim
Duk-Hee Ryu
Original Assignee
Biopol Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040000989A external-priority patent/KR100631108B1/ko
Priority claimed from KR1020040098455A external-priority patent/KR100667292B1/ko
Application filed by Biopol Co., Ltd. filed Critical Biopol Co., Ltd.
Publication of WO2005065604A1 publication Critical patent/WO2005065604A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/01—Non-adhesive bandages or dressings
    • A61F13/01034—Non-adhesive bandages or dressings characterised by a property
    • A61F13/01042—Absorbency
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/06—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings
    • A61F13/064—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings for feet
    • A61F13/069—Decubitus ulcer bandages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00157—Wound bandages for burns or skin transplants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00217—Wound bandages not adhering to the wound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00217—Wound bandages not adhering to the wound
    • A61F2013/00229—Wound bandages not adhering to the wound with alginate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00246—Wound bandages in a special way pervious to air or vapours
    • A61F2013/00251—Wound bandages in a special way pervious to air or vapours with macroscopic openings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00365—Plasters use
    • A61F2013/00519—Plasters use for treating burn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00855—Plasters pervious to air or vapours
    • A61F2013/00859—Plasters pervious to air or vapours with macroscopic openings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00927—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors
    • A61F2013/00931—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors chitin

Definitions

  • the present invention relates, in general, to an occlusive wound dressing for use in covering and protecting wounds and promoting wound healing through direct contact with wounds. More particularly, the present invention relates to a wound dressing which is excellent in absorptivity, waterproofing ability, moisture permeability, non-adherence to wounds and an ability to create an appropriate moist environment.
  • the skin is an organ that protects the body against external stimuli and microbial invasion and functions to prevent water loss from the body and control body temperature. Wounds, whether the skin is damaged, burned or otherwise traumatized, cause the skin to lose its full function, at least in the wound area, resulting in several side effects caused by water loss and microbial infection. In severe cases, the wound area is difficult to cure, or secondary functional disorder or damage occurs . In the worst case, wounds may be fatal to the patient. Therefore, it is essential to dress wounds using proper dressings in order to help wounds heal more quickly and minimize secondary side effects . Major factors involved in wound healing include moisture environment, microbial infection, debris, necrotized tissues, temperature, oxygen concentration and pH.
  • ideal dressings are those which meet the following requirements: maintenance of an appropriate moist environment at the face contacting the wound, rapid absorption of exudates from the wound, easy attachment to and removal from the wound, gas/moisture vapor permeability, heat insulation against the exterior, defense against bacterial infection, harmlessness to the body, and economic benefits .
  • Conventional gauze and non-woven dressings can absorb exudates from wounds well, but can neither defend against bacterial infection nor create moist conditions at wound sites, thus retarding wound healing.
  • gauze and non-woven dressings are apt to hold fast to wounds, they may damage newly generated tissue with accompaniment of discomfort upon their removal. Further, lints removed from the surface of the dressings remain on the wounds.
  • film-type dressings are convenient in use and easy to be manufactured, but have poor absorptivity, and is thus limited in use.
  • the other dressings have significant problems with respect to convenience in use, easiness in manufacture and economic benefits .
  • U.S. Pat. Nos. 4,202,800, 4,367,327 and 4,686,137 disclose polyurethane films prepared using hydrophilic polyols, which can be used as dressings.
  • the film-type dressings are useful for slight wounds, such as abrasions or erosions, and skin graft donor sites, but not suitable for wounds generating a large quantity of exudates due to their properties of poor moisture permeability and absorptivity.
  • the film-type dressings are convenient to use and easy to manufacture, but can be used only on very slight wounds due to their poor exudate absorptivity and moisture permeability.
  • an object of the present invention is to provide a wound dressing including a microporous polyurethane film layer that contacts wounds and contains micropores, and a means for absorbing highly viscous wound exudates on a wound-contacting surface, with which excellent absorptivity to wound exudates and non-adherence to wounds are provided. It is another object of the present invention to provide a wound dressing which includes a highly-absorptive fibrous absorbent sheet that provides an appropriate moist environment to wounds and is applicable to a variety of wounds, from slight wounds to wounds generating large amounts of exudate, such as ulcerations or burns.
  • the present invention provides a wound dressing, including a wound contacting layer that is made of a microporous polyurethane film, contains a plurality of micropores with an average diameter of 5-80 ⁇ m and a means for absorbing highly viscous wound exudates, and is 10-200 ⁇ m thick, and a supporting layer that is combined with an upper surface of the wound contacting layer.
  • the supporting layer is composed of a base sheet layer and/or a fibrous absorbent sheet layer with high absorptivity.
  • the means for absorbing highly viscous wound exudates is a plurality of macropores 100-1,000 ⁇ m in diameter and/or slits 0.1-10 mm long.
  • the dressing according to the present invention preferably has an outer protective film layer that is combined with an upper surface of the supporting layer.
  • the wound dressing according to the present invention has a multi-layered structure including a wound contacting layer that is made of a microporous polyurethane film having absorptivity to wound exudates and non-adherence to wounds, a base sheet layer (or a fibrous absorbent layer) that supports the wound contacting layer and holds absorbed wound exudates, and preferably an outer protective film layer that prevents the infiltration of external bacteria and impurities and maintains suitable moisture permeability.
  • the thickness and form of the wound dressing may vary depending on the intended purpose.
  • the wound dressing has, but is not limited to, a thickness ranging from 0.1 mm to 10 mm.
  • the dressing of the present invention Due to its properties of non-adherence to wounds, high exudate absorptivity, formation of a suitable moist environment, defense against infiltration of external impurities, etc., the dressing of the present invention has excellent wound healing effect, is applicable to diverse wounds from slight wounds to severe wounds generating a large quantity of exudates, and causes no discomfort upon changing by no adherence to wounds .
  • Fig. 1 is a schematic cross sectional view of a dressing according to a first embodiment of the present invention
  • Fig. 2 is a schematic cross sectional view of a dressing according to a second embodiment of the present invention
  • Fig. 3 is a schematic sectional view of a surface of a wound contacting layer of the dressing of Fig. 1 or Fig. 2
  • Fig. 4 is a scanning electron microphotograph (SEM) showing a surface of a microporous polyurethane film prepared in a Preparation Example of the present invention
  • FIG. 5 is a schematic cross sectional view of a dressing according to a third embodiment of the present invention
  • Fig. 6 is a schematic cross sectional view of a dressing according to a fourth embodiment of the present invention
  • Fig. 7 is a schematic cross sectional view of a dressing according to a fifth embodiment of the present invention.
  • the term “combined” refers to all of states at which components (layers) of a dressing are bound to each other by a binding means, such as an adhesive, thermal compression or microwaves, which one component (first layer) is bound to another component (second layer) by coating a solution comprising the first layer onto the second layer, and which layers are simply layered without this binding.
  • a binding means such as an adhesive, thermal compression or microwaves, which one component (first layer) is bound to another component (second layer) by coating a solution comprising the first layer onto the second layer, and which layers are simply layered without this binding.
  • the dressing according to the present invention includes at least a wound contacting layer 10 that directly contacts wounds and a supporting layer to support the wound contacting layer 10.
  • Fig. 1 is a schematic cross sectional view of a dressing according to a first embodiment of the present invention, in which the dressing has a double-layered structure consisting of the wound contacting layer 10 and the base sheet layer 20.
  • FIG. 2 is a schematic cross sectional view of a dressing according to a second embodiment of the present invention, in which the dressing has a double-layered structure consisting of the wound contacting layer 10 and the fibrous absorbent layer 30 with high absorptivity.
  • the wound contacting layer 10 is made of a microporous polyurethane film that is 10-200 ⁇ m thick and has a microporous structure.
  • the wound contacting layer 10 is a microporous structure having a plularity of micropores 12 with an average diameter of 5-80 ⁇ m.
  • the wound contacting layer 10 includes a small amount of a means for absorbing highly viscous wound exudates .
  • the means for absorbing highly viscous wound exudates is a plurality of micropores 14 having a diameter of 100-1,000 ⁇ m and/or a plurality of slits 15 having a length of 0.1-10 mm.
  • Fig. 3 is a schematic sectional view of the wound contacting layer 10 of the dressing of Fig. 1 or Fig. 2. As shown in Fig.
  • the wound contacting layer 10 may have a structure containing a plurality of micropores 12 with an average diameter of 5-80 ⁇ m and a plurality of macropores 14 with a diameter of 100-1,000 ⁇ m, a structure containing a plurality of micropores 12 with an average diameter of 5-80 ⁇ m and a plurality of slits 15 0.1-10 mm long, or a structure containing a plurality of micropores 12 with an average diameter of 5-80 ⁇ m, a plurality of macropores 14 with a diameter of 100-1,000 ⁇ m and a plurality of slits 15 0.1-10 mm long.
  • Fig. 3 shows a structure containing micropores 12, macropores 14 and slits 15.
  • the wound contacting layer 10 has excellent absorptivity to wound exudates and non-adherence to wounds. Also, this surface of the wound contacting layer 10 does not adhere to wounds, thereby preventing regenerated tissues from being damaged and reducing the discomfort of patients when being exchanged with a new dressing.
  • the wound contacting layer 10 is prepared by coating the supporting layer (i.e., base sheet layer or fibrous absorbent layer) with a polyurethane solution and allowing the polyurethane solution to coagulate to lead to conjugation with the surface of the supporting layer.
  • the wound contacting layer 10 is prepared by coating the polyurethane solution on a release paper, allowing the polyurethane solution to coagulate to generate a film and conjugating the film to the supporting layer. During coagulation of the polyurethane solution, a plurality of micropores 12 with an average diameter of 5-80 ⁇ m are generated. A plurality of macropores 14 with an average diameter of 100-1,000 ⁇ m or slits 15 as a means for absorbing highly viscous wound exudates may be formed by a mechanical method.
  • the preparation of the wound contacting layer 10 will be described in detail, as follows.
  • the polyurethane solution used in the preparation of the wound contacting layer 10 is a mixture prepared by mixing a polyurethane resin synthesized using isocyanate, polyols and a chain extender with a solvent.
  • the polyurethane solution may further include a hydrophilic agent and an antifungal agent.
  • the polyurethane resin is prepared as follows. A polyol and a chain extender are added to a reactor and mixed with each other with sufficient stirring. After the reactor is heated to 70-80°C, isocyanate is added over several times to the reactor to increase the viscosity of the mixture. When the viscosity of the mixture increases, a solvent is added over several times to control the viscosity of the mixture.
  • the isocyante used in the synthesis of the polyurethane resin is one or more selected from among isoporone diisocyanate, hexamethylenediisocyanate, lysine diisocyanate, trimethylhexamethylene diisocyanate, 2,2-bis- 4' -propaneisocyanate, 2, 4-toluenediisocyanate and its isomers, 4, 4' -biphenylenediisocyanate, 4,4- dicyclohexylmethanediisocyanate, 1, 4-xylenediisocyanate, 1, 3-xylenediisocyanate.
  • the isocyanate is selected from among 4, 4' -biphenylenediisocyanate, isoporone diisocyanate and hexamethylenediisocyanate.
  • the polyols include a polypropylene glycol which contains at least two hydroxyl groups and ranges in a molecular weight from 200 to 3,000, an ethylene oxide/propylene oxide random copolymer which contains at least two hydroxyl groups and ranges in molecular weight from 3,000 to 6,000, a polyetherpolyol such as polytetramethylglycol which contains at least two hydroxyl groups and ranges in molecular weight from 1,000 to 3,000, a polyesterpolyol ranging in molecular weight from 500 to 3,500, and mixtures thereof.
  • the chain extender To function as the chain extender, at least two intramolecular hydroxyl groups are required.
  • the chain extender include 1, 3-butanediol, 1, 4-butanediol, 1,5- pentanediol, 1, 6-hexanediol, neophentylglycol, propyleneglycol, ethylene glycol, glycerol, trimethylolethane, trimethylolpropane, esterglycol, and mixtures thereof.
  • Preferred are 1, 3-butanediol, 1,4- butanediol, ethylglycol and 1, 6-hexanediol .
  • the solvent used as a viscosity controller of the polyurethane resin should have high hydrophilicity. Examples of the viscosity controller include dimethylacetamide
  • the polyurethane resin synthesized as described above is combined in a film form to the supporting layer by a coagulation process through precipitation or selective evaporation.
  • the coagulation precipitation is carried out, as follows.
  • the polyurethane resin is dissolved in a highly water-miscible solvent to generate a low viscosity polyurethane solution.
  • the polyurethane solution is coated onto the supporting layer.
  • the supporting layer is then immersed in a coagulation bath to coagulate the polyurethane resin.
  • the highly water-miscible solvent contained in the polyurethane solution gets out to water while the polyurethane resin is coagulated, resulting in the generation of a film containing a plurality of micropores 12 on a surface of the supporting layer in an adherent state.
  • the polyurethane resin is dissolved in a mixture of a nonsolvent that is for the polyurethane resin and has a high boiling point and a solvent that is for the polyurethane resin and has a low boiling point.
  • the resulting polyurethane solution is coated onto the supporting layer, and the supporting layer is then heat-dried.
  • Fig. 4 is a scanning electron microphotograph (SEM) showing a surface of a microporous polyurethane film prepared in a Preparational Example of the present invention, in which a plurality of micropores 12 is formed by the precipitation coagulation process.
  • SEM scanning electron microphotograph
  • the wound contacting layer 10 is primarily prepared on a release paper, as follows: the polyurethane resin is coated on the release paper, and the polyurethane resin is then coagulated to develop a film containing a plurality of micropores 12, that is, the wound contacting layer 10.
  • the wound contacting layer 10 is detached from the release paper and combined with a surface of the supporting layer, for example, by a thermal compression method.
  • a plurality of macropores 14 of 100-1,000 ⁇ m and/or a plurality of slits 15 of 0.1-10 mm are formed by a mechanical method such as perforation or cutting.
  • the polyurethane solution used in the preparation of the wound contacting layer 10 may further include a highly absorbable resin as a hydrophilic agent to increase the absorptivity of the dressing according to the present invention.
  • the highly absorbable resin is one or more selected from the group consisting of L-62, L-64, P-84, P-85, P-105, F-68, F-87, F-88, F-108, and F-127, all of which are kinds of ethylene oxide/propylene oxide block copolymers, manufactured by BASF, Germany, hyaluronic acid, carboxymethylcellulose, pectin, Guar gum, sodium alginate, chitin, chitosan, gelatin, starch, hydroxyethylcellulose, xanthan gum, and karaya gum.
  • the polyurethane solution may further include an anitfungal agent to improve the antifungal activity of the dressing.
  • the anitfungal agent is one or more selected from among silver sulfur diazine, chlorohexidin, povidone iodine, idocaine, ginosolt, vibriocin, hexachlorophene, chlorotetracycline, neomycin, penicillin, gentamycin, acrinol, etc.
  • the supporting layer consists of a base sheet layer 20 and/or a fibrous absorbent sheet layer 30 with high absorptivity.
  • the base sheet layer 20 is composed of one or more base sheets.
  • the base sheet is selected from among non-woven fabrics, woven fabrics and clothes, which all are prepared by using natural fibers or synthetic fibers, such as polyester, polyethylene, polypropylene, nylon, acryl, rayon, silk and cotton. Preferred are those which has proper supporting ability and high absorptivity.
  • the fibrous absorbent sheet layer 30 is composed of one or more absorbent sheets with high absorptivity.
  • the absorbent sheet is prepared by gathering a synthetic fiber or a natural fiber into a cotton wool form and processing the cotton wool into a sheet.
  • the absorbent layer is made of any one with high absorptivity among base sheets such as non-woven fabrics, woven fabrics and clothes, which all are prepared using natural fibers or sythetic fibers, or a highly absorbable sheet that is prepared by conjugating a highly absorbable fiber, polymer or natural material to such a base sheet, for example, by a dispersion method.
  • the fibrous absorbent layer is composed of a base sheet such as non-woven fabrics, woven fabrics and clothes, which all are prepared using natural fibers or sythetic fibers, and a highly absorbable polymer or natural material to be mixed with the base sheet.
  • the fibrous absorbent layer 30 is composed of a base sheet that is mixed, for example, by dispersion or impregnation, with one or more selected from the group consisting of highly absorbable polymers and natural materials, which are exemplified by polyacrylic acid, polysulfonates, polyacrylates, polyvinylalcohol, polyoxyethylene, polyethyleneoxide, polysaccharides, polymetacrylate, polyacrylamide and cellulose, carboxymethylcellulose, pectin, Guar gum, sodium alginate, chitin, chitosan, gelatin, starch, hydroxyethylcellulose, xanthan gum, pulp and karaya gum.
  • highly absorbable polymers and natural materials which are exemplified by polyacrylic acid, polysulfonates, polyacrylates, polyvinylalcohol, polyoxyethylene, polyethyleneoxide, polysaccharides, polymetacrylate, polyacrylamide and cellulose, carboxymethylcellulose, pectin, Guar gum, sodium al
  • the fibrous absorbent layer 30 may form a proper moist environment and has a proper absorptivity, which are determined depending on the kind and amount of the highly absorbable polymer and natural material .
  • the fibrous absorbent layer 30 may have a high exudate absorptivity to absorb over 400% by weight based on the weight thereof and an excellent retention ability to prevent leakage of wound exudates.
  • Fig. 5 is a schematic cross sectional view of a dressing according to a third embodiment of the present invention. As shown in Fig.
  • the dressing according to the third embodiment has a three-ply structure consisting of a wound contacting layer 10, a base sheet layer 20 and a fibrous absorbent layer 30, which are combined in the sequence starting from the bottom contacting wounds of the dressing.
  • This three-ply structure provides sufficient supporting ability, in particular, and excellent absorptivity and retention ability for wound exudates, and thus, allows the dressing to be applied to diverse wounds generating a large quantity of exudates, and is useful when the relatively frequent exchange of dressing is required.
  • Fig. 6 is a schematic cross sectional view of a dressing according to a fourth embodiment of the present invention. As shown in Fig.
  • the dressing according to the fourth embodiment has a three-ply structure consisting of a wound contacting layer 10, a base sheet layer 20 or a fibrous absorbent layer 30, and an outer protective film layer 40, which are combined in the sequence starting from the bottom contacting wounds of the dressing.
  • This three-ply structure contains the base sheet layer 20 or the fibrous absorbent layer 30 between the wound contacting layer 10 and the outer protective film layer 40.
  • Fig. 7 is a schematic cross sectional view of a dressing according to a fifth embodiment of the present invention. As shown in Fig.
  • the dressing according to the fifth embodiment has a four-ply structure consisting of a wound contacting layer 10, a base sheet layer 20, a fibrous absorbent layer 30 and an outer protective film layer 40, which are combined in the sequence starting from the bottom contacting wounds of the dressing.
  • the outer protective film layer 40 of the dressings according to the fourth embodiment (Fig. 6) and the fifth embodiment (Fig. 7) is a moist permeable film 10-200 ⁇ m thick.
  • the outer protective film layer 40 is a non-porous film and has high moisture permeability and waterproofing ability. This outer protective film layer 40 functions to defense against invasion of bacteria and impurities, prevent leakage of wound exudates and maintain an appropriate moisture permeability.
  • the outer protective film layer 40 stimulates wound healing by providing an appropriate moist environment to wounds.
  • the outer protective film layer 40 may be made of a polymer film which is prepared using polyurethane, polyethylene, polypropylene, polyvinylchloride, etc. Preferred is a film with a moisture permeability of 300- 2,000 g/m 2 /24 hrs. [Mode for Invention] A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as the limit of the present invention.
  • a polyurethane resin was prepared, as follows. To a 3- L flask filled with nitrogen gas, 0.2 mole of polyethylene glycol with a molecular weight of 2,000, 0.8 mole of polytetramethylene glycol with a molecular weight of 2,000, 0.4 mole of polyesterpolyol with a molecular weight of 3,000, 3 mole of 1, 4-butanediol and dimethylformamide (DMF) were added. After sufficient mixing with stirring, the reactor was heated to 70-80°C, diphenylmethanediisocyanate was added over several times to increase viscosity of the mixture. When the viscosity of the mixture increased, a solvent was added over several times to control the viscosity of the mixture.
  • DMF dimethylformamide
  • a polyurethane resin was prepared, as follows. To a 3- L flask filled with nitrogen gas, 0.2 mole of polyethylene glycol with a molecular weight of 2,000, 0.8 mole of polytetramethylene glycol with a molecular weight of 2,000, 0.4 mole of polyesterpolyol with a molecular weight of 3,000, 3 mole of 1, 4-butanediol and dimethylformamide (DMF) were added. After sufficient mixing with stirring, the reactor was heated to 70-80°C, diphenylmethanediisocyanate was added over several times to increase viscosity of the mixture. When the viscosity of the mixture increased, a solvent was added over several times to control the viscosity of the mixture.
  • DMF dimethylformamide
  • DMF dimethylformamide
  • MEK methylethylketone
  • the polyurethane solution prepared in Synthesis Example 1 was coated on a non-woven fabric (Vilen Co. Ltd., Korea) into a thickness of 500 ⁇ m. The non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min. The polyurethane was coagulated while forming a white microporous membrane containing micropores 12. The coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min. The dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • Fig. 1 shows the structure of the dressing prepared in this Example. The dressing was evaluated for physical properties in the following processes and the measured results are given in Table 1, below.
  • Thickness Thickness of the dressing was measured at three regions using a dial micrometer, and a mean value was calculated using the measured values .
  • Pore size The dressing was measured for pore size using a scanning electron microscope.
  • the polyurethane solution prepared in Synthesis Example 2 was coated on a non-woven fabric (Vilen Co. Ltd., Korea) into a thickness of 500 ⁇ m. The non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min. The polyurethane was coagulated while forming a white microporous membrane containing micropores 12. The coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min. The dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • Fig. 1 shows the structure of the dressing prepared in this Example. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • the polyurethane solution prepared in Synthesis Example 2 was coated on a non-woven fabric (Vilen Co. Ltd., Korea) into a thickness of 500 ⁇ m.
  • the non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min.
  • the polyurethane was coagulated while forming a white microporous membrane containing micropores 12.
  • the dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • a non-woven fabric absorbent sheet (0.3 mm thick, Baiksan T&S Co. Ltd., Korea) was layered. Then, the moisture permeable polyurethane film, prepared in Preparation Example of an outer protective film, was layered on the non-woven fabric absorbent sheet.
  • Fig. 6 shows the structure of the resulting dressing. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • Example 2 was coated on a non-woven fabric (Vilen Co. Ltd.,
  • the non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min.
  • the polyurethane was coagulated while forming a white microporous membrane containing micropores 12.
  • the coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min.
  • the dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • a non-woven fabric absorbent sheet (0.3 mm thick, Baiksan T&S Co.
  • a highly absorbable polymer (GE- 600, Kolon Industries, Inc., Korea) was dispersed to be laminated on the non-woven fabric absorbent sheet at an amount 10 g/m 2 .
  • the moisture permeable polyurethane film, prepared in Preparation Example of the outer protective film was layered on the highly absorbable polymer.
  • Fig. 6 shows the structure of the resulting dressing. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • Example 2 was coated on a non-woven fabric (Vilen Co. Ltd.,
  • the non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min.
  • the polyurethane was coagulated while forming a white microporous membrane containing micropores 12.
  • the coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min.
  • the dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • a non-woven fabric absorbent sheet (0.3 mm thick, Baiksan T&S Co.
  • a highly absorbable polymer (GE- 600, Kolon Industries, Inc., Korea) was dispersed to be laminated on the non-woven fabric absorbent sheet at an amount 20 g/m 2 .
  • the moisture permeable polyurethane film, prepared in Preparation Example of the outer protective film was layered on the highly absorbable polymer.
  • Fig. 6 shows the structure of the resulting dressing. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • Example 2 was coated on a non-woven fabric (Vilen Co. Ltd.,
  • the non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min.
  • the polyurethane was coagulated while forming a white microporous membrane containing micropores 12.
  • the coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min.
  • the dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • a non-woven fabric absorbent sheet (1.0 mm thick, Baiksan T&S Co.
  • a highly absorbable polymer (GE- 600, Kolon Industries, Inc., Korea) was dispersed to be laminated on the non-woven fabric absorbent sheet at an amount 20 g/m 2 .
  • the moisture permeable polyurethane film, prepared in Preparation Example of the outer protective film was layered on the highly absorbable polymer.
  • Fig. 6 shows the structure of the resulting dressing. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • Example 2 was coated on a non-woven fabric (Vilen Co. Ltd., Korea) into a thickness of 500 ⁇ m.
  • the non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min.
  • the polyurethane was coagulated while forming a white microporous membrane containing micropores 12.
  • the coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min.
  • the dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • a non-woven fabric absorbent sheet (2.0 mm thick, Baiksan T&S Co. Ltd., Korea) was layered. Then, a highly absorbable polymer (GE- 600, Kolon Industries, Inc., Korea) was dispersed to be laminated on the non-woven fabric absorbent sheet at an amount 20 g/m 2 . Then, the moisture permeable polyurethane film, prepared in Preparation Example of the outer protective film, was layered on the highly absorbable polymer.
  • Fig. 6 shows the structure of the resulting dressing. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • Example 2 was coated on a non-woven fabric (Vilen Co. Ltd., Korea) into a thickness of 500 ⁇ m.
  • the non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min.
  • the polyurethane was coagulated while forming a white microporous membrane containing micropores 12.
  • the coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min.
  • the dried specimen was mechanically perforated into a diameter of 1,000 ⁇ m to generate fifteen macropores 14 per cm 2 .
  • a non-woven fabric absorbent sheet (0.5 mm thick, Baiksan T&S Co. Ltd., Korea) was layered. Then, a highly absorbable polymer (KANEBO Ltd., Japan) was dispersed to be laminated on the non-woven fabric absorbent sheet. Then, the moisture permeable polyurethane film, prepared in Preparation Example of the outer protective film, was layered on the highly absorbable polymer.
  • Fig. 7 shows the structure of the resulting dressing. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • the polyurethane solution prepared in Synthesis Example 2 was coated on a non-woven fabric (Vilen Co. Ltd.,
  • the non-woven fabric was then immersed in a coagulation bath containing a 30% DMF solution and maintained at 30°C. The coagulation was carried out for 30 min.
  • the polyurethane was coagulated while forming a white microporous membrane containing micropores 12.
  • the coagulated specimen was fixed on a dry support by squeezing and subjected to hot air drying in a dry oven at 100°C for 20 min. The dried specimen was partially cut into a length of 1 mm to generate five slits 15 per cm 2 .
  • a non-woven fabric absorbent sheet (0.5 mm thick, Baiksan T&S Co. Ltd., Korea) was layered.
  • a highly absorbable polymer (KANEBO Ltd., Japan) was dispersed to be laminated on the non-woven fabric absorbent sheet. Then, the moisture permeable polyurethane film, prepared in Preparation Example of the outer protective film, was layered on the highly absorbable polymer.
  • Fig. 7 shows the structure of the resulting dressing. The dressing was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • a commercially available product (Brand Name: Medicsband, non-woven dressing) , manufactured by the N Company in Korea, was used as a comparative sample. This sample was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • COMPARATIVE EXAMPLE 2 A commercially available sterile gauge, manufactured by the D Company in Korea, was used as a comparative sample. This sample was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • a commercially available product (Brand Name: Medilon, non-woven dressing) , manufactured by the P Company in Korea, was used as a comparative sample. This sample was evaluated for physical properties according to the same processes as in Example 1, and the measured results are given in Table 1, below.
  • the dressings effectively provided moist environments by its increased absorptivity by the sheet made of the microporous polyurethane film on the non-woven fabric and the fibrous absorbent sheet layer. Also, the employment of the highly absorbable polymer was found to facilitate the control of the absorptivity of the absorbent sheet layer 30. Therefore, through the control of the absorptivity of the absorbent layer, the dressings can be applied to diverse wounds from slight wounds to wounds generating a large quantity of exudates, such as ulcerations or burns. As apparent from the data of Examples 1 and 2, when including the hydrophilic agent, the polyurethane solution was found to form larger pores than the case of not containing the hydrophilic agent.
  • the present invention greatly improved the disadvantages of the conventional non- woven fabric or gauge dressings, including generation of dry environments, relatively low absorptivity compared to their thickness and adherence to wounds.
  • the dressing of the present invention has excellent wound healing effect when applied to wounds.
  • the wound contacting layer contains both micropores and a mean (macropores or slits) for absorbing highly viscous wound exudates
  • the dressing of the present invention rapidly absorbs low viscosity exudates as well as high viscosity exudates, and has non-adherence to wounds .
  • the dressing having this structure can be applied diverse wounds from slight wounds to severe wounds generating a large quantity of exudates .
  • the dressing stimulates wound healing by defending against the infiltration of bacteria and other external impurities, preventing the leakage of wound exudates and providing an appropriate moist environment .
  • the dressing of the present invention has excellent wound healing effect, is applicable to diverse wounds from slight wounds to severe wounds generating a large quantity of exudates, and causes no discomfort upon changing by no adherence to wounds .

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un pansement qui protège les plaies par le contact direct avec celles-ci. Ce pansement comprend une couche de contact avec la plaie qui est faite d'un film de polyuréthanne microporeux, contient une pluralité de micropores d'un diamètre moyen de 5 à 80 νm ainsi qu'un moyen d'absorption d'exsudats de plaie hautement visqueux, et qui a une épaisseur de 10 à 200 νm. Le pansement selon l'invention comprend en outre une couche qui est combinée avec une surface supérieure de la couche de contact avec la plaie. La couche support est composé d'une feuille de base et/ou une feuille absorbante fibreuse à grand pouvoir d'absorption. Le moyen d'absorption d'exsudats de plaie hautement visqueux est constitué d'une pluralité de macropores d'un diamètre de 100 à 1000 νm et/ou de fentes d'une longueur de 0,1 à 10 mm. De préférence, le pansement comprend également un film de protection extérieur qui est combiné avec une surface supérieure de la couche de support. Du fait de ses caractéristiques structurelles, le pansement selon l'invention présente une excellente capacité de non adhésion et un grand pouvoir d'absorption d'exsudats tout en évitant que des bactéries et des impuretés externes s'y infiltrent et en procurant un environnement humide approprié aux plaies, favorisant ainsi la guérison de la plaie.
PCT/KR2004/003201 2004-01-07 2004-12-07 Pansement WO2005065604A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020040000989A KR100631108B1 (ko) 2004-01-07 2004-01-07 창상피복용 드레싱재
KR10-2004-0000989 2004-01-07
KR1020040098455A KR100667292B1 (ko) 2004-11-29 2004-11-29 창상피복용 드레싱재
KR10-2004-0098455 2004-11-29

Publications (1)

Publication Number Publication Date
WO2005065604A1 true WO2005065604A1 (fr) 2005-07-21

Family

ID=34752247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2004/003201 WO2005065604A1 (fr) 2004-01-07 2004-12-07 Pansement

Country Status (1)

Country Link
WO (1) WO2005065604A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009106496A1 (fr) * 2008-02-27 2009-09-03 Basf Se Matériau composite multicouche, fabrication et utilisation associées
WO2009106501A1 (fr) * 2008-02-27 2009-09-03 Basf Se Matériau composite multicouche, fabrication et utilisation associées
WO2009004282A3 (fr) * 2007-07-01 2009-12-23 Stephen Thomas Pansement médical
DE102009019646A1 (de) * 2009-04-30 2010-11-25 Lohmann & Rauscher GmbH, Schönau Wundabdeckung und Wundversorgungskit
CN103860328A (zh) * 2012-12-18 2014-06-18 深圳市爱杰特医药科技有限公司 带有渗液缝的医用干/湿膜
CN104840302A (zh) * 2014-02-18 2015-08-19 株式会社元比金 层合有粘合膜的敷料及其制造方法
WO2016020703A1 (fr) * 2014-08-08 2016-02-11 Medtrade Products Limited Pansement pour plaies
WO2016020704A1 (fr) * 2014-08-08 2016-02-11 Medtrade Products Limited Pansement pour plaies
CN105476756A (zh) * 2014-07-06 2016-04-13 储诚浩 提高美容用理疗贴的粘贴效果及药性的方法
ITUA20162781A1 (it) * 2016-04-21 2017-10-21 Fabrizio Bracchetti Kit di medicamenti per l’uso nel trattamento di lesioni dei tessuti tegumentari.
CN108042840A (zh) * 2017-12-28 2018-05-18 广州润虹医药科技股份有限公司 一种医用海绵
CN119974693A (zh) * 2025-04-11 2025-05-13 泉州市百丝达无纺布有限公司 一种超柔防形变医疗无纺布及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4773409A (en) * 1985-09-20 1988-09-27 E. R. Squibb & Sons, Inc. Wound dressing
US4860737A (en) * 1981-02-13 1989-08-29 Smith And Nephew Associated Companies P.L.C. Wound dressing, manufacture and use
US6077526A (en) * 1995-05-17 2000-06-20 Texon Uk Limited Wound dressing
KR20010081190A (ko) * 2000-02-10 2001-08-29 박명환 미세다공성 폴리우레탄 필름 부착 부직포 드레싱재
EP1374812A1 (fr) * 2002-06-28 2004-01-02 Biopol Co., Ltd. Pansement de mousse microporeux multi-couche et son procédé de fabrication

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4860737A (en) * 1981-02-13 1989-08-29 Smith And Nephew Associated Companies P.L.C. Wound dressing, manufacture and use
US4773409A (en) * 1985-09-20 1988-09-27 E. R. Squibb & Sons, Inc. Wound dressing
US6077526A (en) * 1995-05-17 2000-06-20 Texon Uk Limited Wound dressing
KR20010081190A (ko) * 2000-02-10 2001-08-29 박명환 미세다공성 폴리우레탄 필름 부착 부직포 드레싱재
EP1374812A1 (fr) * 2002-06-28 2004-01-02 Biopol Co., Ltd. Pansement de mousse microporeux multi-couche et son procédé de fabrication

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004282A3 (fr) * 2007-07-01 2009-12-23 Stephen Thomas Pansement médical
WO2009106496A1 (fr) * 2008-02-27 2009-09-03 Basf Se Matériau composite multicouche, fabrication et utilisation associées
WO2009106501A1 (fr) * 2008-02-27 2009-09-03 Basf Se Matériau composite multicouche, fabrication et utilisation associées
US20170355325A1 (en) * 2008-02-27 2017-12-14 Basf Se Multi-layer composite material, production and use thereof
DE102009019646A1 (de) * 2009-04-30 2010-11-25 Lohmann & Rauscher GmbH, Schönau Wundabdeckung und Wundversorgungskit
DE102009019646B4 (de) * 2009-04-30 2015-04-30 Lohmann & Rauscher Gmbh Wundabdeckung und Verfahren zum Herstellen
CN103860328A (zh) * 2012-12-18 2014-06-18 深圳市爱杰特医药科技有限公司 带有渗液缝的医用干/湿膜
CN104840302A (zh) * 2014-02-18 2015-08-19 株式会社元比金 层合有粘合膜的敷料及其制造方法
CN105476756A (zh) * 2014-07-06 2016-04-13 储诚浩 提高美容用理疗贴的粘贴效果及药性的方法
CN105476756B (zh) * 2014-07-06 2019-05-17 范荣辉 提高美容用理疗贴的粘贴效果及药性的方法
WO2016020703A1 (fr) * 2014-08-08 2016-02-11 Medtrade Products Limited Pansement pour plaies
WO2016020704A1 (fr) * 2014-08-08 2016-02-11 Medtrade Products Limited Pansement pour plaies
EP3177244B2 (fr) † 2014-08-08 2025-07-09 Medtrade Products Limited Pansement pour plaies
EP3177244B1 (fr) 2014-08-08 2022-03-23 Medtrade Products Limited Pansement pour plaies
US12303355B2 (en) 2014-08-08 2025-05-20 Medtrade Products Limited Wound dressing
US12090028B2 (en) 2014-08-08 2024-09-17 Medtrade Products Limited Wound dressing
ITUA20162781A1 (it) * 2016-04-21 2017-10-21 Fabrizio Bracchetti Kit di medicamenti per l’uso nel trattamento di lesioni dei tessuti tegumentari.
WO2017182989A1 (fr) * 2016-04-21 2017-10-26 Bracchetti Fabrizio Trousse de médication adaptée pour traiter des lésions des tissus tégumentaires
CN108042840B (zh) * 2017-12-28 2021-04-06 广州润虹医药科技股份有限公司 一种医用海绵
CN108042840A (zh) * 2017-12-28 2018-05-18 广州润虹医药科技股份有限公司 一种医用海绵
CN119974693A (zh) * 2025-04-11 2025-05-13 泉州市百丝达无纺布有限公司 一种超柔防形变医疗无纺布及其制备方法
CN119974693B (zh) * 2025-04-11 2025-07-25 泉州市百丝达无纺布有限公司 一种超柔防形变医疗无纺布及其制备方法

Similar Documents

Publication Publication Date Title
US6103369A (en) Multi-layered dressing
SU741779A3 (ru) Перев зочный материал дл иммобилизации
US6680113B1 (en) Multi-layered dressing
US4838253A (en) Silicone gel coated permeable wound dressing
US6793645B2 (en) Multi-layered wound dressing
US5527271A (en) Thermoplastic hydrogel impregnated composite material
KR101787192B1 (ko) 항균 드레싱재 및 그 제조방법
US20040018227A1 (en) Multilayered microporous foam dressing and method for manufacturing the same
US20080014387A1 (en) Foam layer cohesive articles and wound care bandages and methods of making and using same
JPH10505769A (ja) 滲出液処置用スピロソーベント包帯
WO1983003549A1 (fr) Pansement adhesif chirurgical
JPH02147062A (ja) 創傷被覆材
CA1340750C (fr) Substance pour pansement hemostatique de plaie
WO2005065604A1 (fr) Pansement
NO880552L (no) Saarbandasje basert paa polymermateriale.
US5063063A (en) Hypoadherent dressings comprising liquid pervious polymer coating of polyurethane containing siloxane residues
WO2007136176A1 (fr) Pansement à base de mousse de polyuréthanne comportant une couche médicamenteuse et son procédé de fabrication
KR100631108B1 (ko) 창상피복용 드레싱재
JP2993170B2 (ja) 創傷被覆材
KR100359864B1 (ko) 미세다공성 폴리우레탄 필름이 형성된 창상피복용 드레싱재
JPH04303445A (ja) 創傷被覆材
KR100667292B1 (ko) 창상피복용 드레싱재
KR20090034173A (ko) 실크 드레싱재
JPH07313585A (ja) 創傷被覆材
CN117481910A (zh) 一种纳米银抗菌创可贴

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase